Items Tagged ‘hormone-receptor (HR)-positive’

October 5th, 2017

FDA approves new treatment for certain advanced or metastatic breast cancers

By

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy). Verzenio is approved to be given in combination with an endocrine […]

View full entry

Tags: abemaciclib, Breast Cancer, fulvestrant, hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, Metastatic Breast Cancer, News, Precision Cancer Medicine, Verzenio


September 5th, 2016

ASCO Treatment Recommendations for HR+, Metastatic Breast Cancer

By

The American Society of Clinical Oncology (ASCO) recently convened an Expert Panel to create recommendations for endocrine therapy for women with hormone-receptor (HR)-positive, metastatic breast cancer. The panel conducted “a systematic review of evidence from 2008 through 2015 to create recommendations informed by that evidence.” These updates were recently published in the Journal of Clinical […]

View full entry

Tags: Breast Cancer, Endocrine therapy, hormone-receptor (HR)-positive, hormones, metastatic, Metastatic Breast Cancer, News, recommendation